A phase II trial of FLX-787 in Charcot-Marie-Tooth

Trial Profile

A phase II trial of FLX-787 in Charcot-Marie-Tooth

Planning
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs FLX 787 (Primary)
  • Indications Charcot-Marie-Tooth disease
  • Focus Therapeutic Use
  • Acronyms COMMIT
  • Most Recent Events

    • 31 Jul 2017 According to a Flex Pharma media release, company is on track to initiate the trial this quarter and data readouts expected in 2018.
    • 25 Jul 2017 According to a Flex Pharma media release, the trial is expected to initiate in third quarter 2017.
    • 03 May 2017 According to a Flex Pharma media release, the company is planning to submit a protocol to the FDA to start a clinical trial of FLX-787 to treat patients with CMT neuropathy and expects to initiate the study in summer 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top